Dr. Marcus Hompesch is Chief Executive Officer and Chairman of the Board of ProSciento and has led the company since its inception in 2003. He is also editor-in-chief of the journal Endocrinology, Diabetes & Metabolism, a Wiley publication. His career and track record in metabolism-focused clinical R&D, spanning more than 25 years in academic and industry settings, includes contributions to clinical development strategies and early phase research studies for many of the diabetes and related metabolic drugs and devices on the market globally.

Prior to leading ProSciento, Dr. Hompesch was Chief Operating Officer of Profil Institut für Stoffwechselforschung GmbH and, before that, was founder and Chief Executive Officer of the medical technology company Med.IQ. He is an author of more than 100 publications, including peer-reviewed journals and editorials and is a regular peer reviewer for scientific journals relevant to metabolic diseases. He is also an editor and co-author of the textbook Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development.

As a licensed physician in Europe he received his M.D. from the University of Düsseldorf, Germany, and following medical school trained in internal medicine and diabetology at the Klinikum Wuppertal Medical Center. He also was a scientific associate at the Department of Medical Informatics, Bio-Statistics and Epidemiology at the Ruhr University Bochum, Germany.

Brian Mooney is Chief Operating Officer at ProSciento, Inc. Mr. Mooney is a CRO executive with over 25 years of experience, much of it focused on global expansion of operations for mid to large CROs, including Chiltern, Theorem and Pharmaceutical Research Associates International (PRA). Prior to joining ProSciento, he served as Executive Vice President of Strategic Service Provision at Chiltern, a Covance company, where he oversaw the development and advancement of one of their core business segments. Before that, Mr. Mooney was Senior Vice President of Clinical Development and General Manager at Theorem Clinical Research (acquired by Chiltern in 2015) and oversaw the expansion and optimization of the clinical operations footprint at a time of rapid momentum for Theorem as a spin out from parent company Omnicare. Prior to his role at Theorem, over a period of 16 years from 1996 to 2012, he held a succession of leadership positions at PRA, including Senior Vice President of Project Services; Vice President of Global Project Management; and Vice President of Countries Group. Over the course of his tenure at PRA, Mr. Mooney contributed significantly to the company’s global expansion of clinical operations, including implementation of PRA’s Global Project Management Methodology initiative and International Partners program. He received his bachelor’s degree in biology with a minor in chemistry from Trenton State College in Trenton, New Jersey.

David Sockolof is the Chief Financial Officer at ProSciento, Inc. Mr. Sockolof is a finance and operations executive with deep experience in corporate growth strategies. His career within the clinical research industry spans more than 20 years, including his role as Executive Director of Resource and Process Optimization at Labcorp Drug Development where he provided leadership in financial forecasting, expense management, and global resource management.

Prior to his position at Labcorp, Mr. Sockolof held a number of leadership roles at PRA Health Sciences, including Vice President of Finance and Business Operations and, prior to that, Director of Business Operations. During his tenure at PRA, his contributions were instrumental in the company’s evolution from a mid-size company to a leading global CRO, including the implementation of strategic financial frameworks and improved systems for proposals and pricing, project finance and global vendor management.  He received his MBA from George Washington University.

Helge Guenther is ProSciento’s Chief Information Officer. His experience in IT and technology solutions spans more than 20 years, including management of IT operations in highly regulated environments.

Prior to joining ProSciento, Mr. Guenther served as CEO of BIT Group USA and CIO of BIT Group Global, where he oversaw the expansion and optimization of global IT operations. Before that, Mr. Guenther was IT Director at Quest Diagnostics, where he focused on implementing new business solutions in close collaboration with the company’s operations and R&D departments. Prior to his role at Quest Diagnostics, Mr. Guenther was Global Program Manager at Baxter Bioscience, where he oversaw the implementation of Enterprise Resource Planning and related business systems across the company’s locations globally. Mr. Guenther earned his MBA from the University of Duesseldorf, Germany.

Mr. Hernandez is Vice President of ProSciento’s Clinical Research Unit. He is an expert in the field of metabolic clinical research and one of the foremost experts in glucose clamp methodologies and digital wearable technologies for the conduct of clinical trials.

As a Vice President, Moises leads the company’s state-of-art, early phase clinical research unit (CRU) in Chula Vista, CA, and is responsible for overseeing principal investigators, site operations, pharmaceutical services, clinical study management, and ensuring compliance with regulatory requirements. With over 15 years of experience at the company, he has contributed to more than 300 clinical research studies for metabolic therapeutics and devices and has been a member of the company’s senior leadership team for more than eight years, helping to manage company initiatives at a corporate level. He received his Bachelor of Medicine degree from the Universidad Autónoma de Baja California.

Michelle Mazuranic, Ph.D., R.D., is Vice President of Medical and Regulatory Affairs at ProSciento, Inc. She oversees ProSciento’s medical affairs and regulatory consulting services, as well as works with clients to build strategic clinical development programs from early engagement assessment and planning through the completion of multi-site clinical trials. 

Dr. Mazuranic has extensive experience in building and leading global scientific strategies for clinical development, regulatory and medical affairs. Prior to joining ProSciento, Dr. Mazuranic served as Head of Global Medical Affairs at Gan & Lee Pharmaceuticals, where she built the department from the ground up. Prior to that, she served as Director of Global Medical Affairs for the Cardio-Renal and Metabolism Team for a seven-year tenure at AstraZeneca, where she managed strategic relationships with external scientific, academic, and advocacy group organizations and experts. Throughout her career, Dr. Mazuranic has developed and implemented activities to support global and compound-specific strategies, external scientific engagement, medical excellence, and evidence generation. Dr. Mazuranic is a licensed dietitian, completed her M.S. in management from Boston University, and earned her Ph.D. in Public Health and Epidemiology from Walden University.

Lynn Rudolph is Vice President and Chief Human Resources Officer at ProSciento, Inc. Ms. Rudolph has an extensive track record of leading global team development, management, and retention programs for companies in accelerated growth phases. Her career in human resources spans more than 20 years, including management of global human resource operations in highly regulated industries. Her background also includes implementing executive coaching and leadership development programs for individuals and teams. Prior to joining ProSciento, Ms. Rudolph served as the Senior Vice President of Human Resources at RW Baird, where she helped the company build its global talent strategy through innovative career and talent development programs. Before her role at RW Baird, she was Principal at Rudolph Coaching, a boutique executive coaching firm focused on delivering career development programs for emerging leaders in diverse industries. Prior to Rudolph Coaching, she was Vice President of Human Resources at PIMCO, a global asset management company with over $2 trillion of assets under management. Ms. Rudolph earned her BS in Psychology from Northwestern University and was awarded Columbia University’s Coaching Certification. She is also a Hogan Assessments credentialed coach.

Mr. Ustick is Vice President of Global Business Development at ProSciento, Inc. His career in clinical research and business development spans more than 16 years, including nearly 10 years focused on metabolic drug and device development at ProSciento. Casey has held a number of leadership roles within clinical research, including clinical operations, regulatory drug development strategy, budgeting & contracting, and business development, which has provided him a holistic perspective of both operational and business fundamentals in early phase clinical drug development.

During his tenure at ProSciento, Casey has worked with more than 50 sponsors worldwide to help launch their early phase clinical research programs. He has also been instrumental in the company’s global expansion of CRO business initiatives, including expansion of phase 1 clinical activities in Australia, sponsor utilization of NASH PASS® patient access platform, and establishing strategic partnerships with key APAC sponsors. Prior to joining ProSciento, Casey worked at Sessions Plastic Surgery Centre where he received his initial clinical research experience overseeing the site’s contribution to FDA approval of silicone gel-filled implants in 2006. He received his bachelor’s degree from the University of California San Diego.

Dana Wilkins is Vice President of Quality and Regulatory Compliance at ProSciento, where her distinguished career spanning over 25 years has made her a recognized authority in clinical research operations, regulatory compliance, and quality management systems.

Before joining the ProSciento team, Ms. Wilkins served as the Executive Director of Quality Assurance at Rho, Inc. In this role, she played a pivotal part in crafting an advanced quality management system. Her contributions were highlighted by the establishment of a Quality Board and the implementation of robust processes, fostering a culture of quality across every phase of project development.

Ms. Wilkins’ career history also includes significant roles at BioMerieux, Inc., a leader in in-vitro diagnostics. Here, she held various quality leadership positions, including a vital role as a global Quality Board member. In this capacity, she was tasked with upholding and elevating quality standards throughout the realms of Medical Affairs, Clinical Affairs, and Regulatory Affairs. Ms. Wilkins’ leadership played a pivotal role in steering the FDA’s groundbreaking achievement—the clearance of the first 510k IVD product based on meta-analysis. Before her tenure at BioMerieux, she served as the Director of Clinical Research Operations at Lehigh Valley Health Network. Ms. Wilkins is a registered nurse and completed an M.S. in Health Services Administration from the University of St. Francis.